Paliperidone Palmitate
Brand Names: Erzofri Extended-Release, Invega Trinza, Invega Sustenna, Invega Hafyera
Methodology & AI Transparency ⓘ
Paliperidone Palmitate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage erzofri: is indicated for the treatment of: Schizophrenia in adults .
- 2 Real-world patient consensus: Zero-PHI community consensus: 78% favorable across 13 logged regimens (Erzofri Extended-Release, Invega Trinza).
- 3 Typical cash cost range: 30-day cash pricing ranges from $52.61 discount cash to $128.89 walk-in retail (NADAC $1.0891/unit).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Paliperidone Palmitate: orthostatic hypotension (4.8%), application-site erythema (6.3%), mild local dryness (6.8%).
Ask our AI Specialists anything about Paliperidone Palmitate
Paliperidone Palmitate Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage erzofri: is indicated for the treatment of: Schizophrenia in adults . Schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants . ERZOFRI is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 ) Treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants. ( 1 )
12.1 Mechanism of Action Paliperidone palmitate is hydrolyzed to paliperidone . Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone in the listed indications is unclear. However, the drug's effect in schizophrenia could be mediated through a combination of central dopamine Type 2 (D 2) and serotonin Type 2 (5HT 2A ) receptor antagonism.
Following administration (117 mg/.75mL Injection), Paliperidone Palmitate achieves Complete (~100%) parenteral systemic delivery for Paliperidone Palmitate (117 mg/.75mL Injection) bioavailability and rapid intravascular/parenteral onset within 15–45 minutes after paliperidone palmitate administration onset, governed by a Negligible circulating terminal half-life following local Paliperidone Palmitate application terminal half-life through biotransformed through cyp3a4, p-gp pathways with mixed urinary/fecal clearance.
Before initiating Paliperidone Palmitate at 117 mg/.75mL Injection, clinical safety checklists rule out contraindicated in patients with prior serious allergic response to paliperidone palmitate (ndc 72526-105); severe baseline organ impairment where paliperidone palmitate accumulation exceeds safe therapeutic margins. Logged tolerability patterns center on mild local dryness (6.8% of reports), application-site erythema (6.3% of reports), transient stinging (5.6% of reports).
Monitor serum digoxin concentrations when initiating or adjusting Paliperidone Palmitate due to transporter overlap.
Co-prescribing strong CYP3A4 inhibitors or inducers can modify Paliperidone Palmitate metabolic elimination kinetics.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Paliperidone Palmitate (NDC 72526-105)
- Severe baseline organ impairment where Paliperidone Palmitate accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (13 Reports)
Paliperidone Palmitate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Paliperidone Palmitate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone: What a 700-Participant Study Found Paliperidone concentration-time profiles after PP6M and PP3M dosing were adequately described by the popPK model. European journal of drug metabolism and pharmacokinetics • 2024-07-15 • Phase III Randomized Trial | N = 700 | 93/100 | PMID 38769284 ↗ |
| New Insights on Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole: What a 200-Participant Study Found Results were consistent with known safety profiles of AL and PP and support the safety of AL 1064 mg every 2 months initiated using AL NCD plus 30-mg oral aripiprazole. The Journal of clinical psychiatry • 2024-02-28 • Phase III Randomized Trial | N = 200 | 88/100 | PMID 38416865 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of paliperidone palmitate 6-monthly long-acting injectable in Consistent with the global study population, PP6M was noninferior to PP3M in preventing relapse in patients with schizophrenia from the Asia region. Medicine • 2023-08-25 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37653768 ↗ |
| Can This Approach Help? Inside the Latest Research on Model-Informed Clinical Development of Once-Every-6-Month Injection of Consistency of the MIDD approach with observed clinical outcomes confirmed the hypothesis that lower C trough did not lead to increased relapse rates at the doses administered. European journal of drug metabolism and pharmacokinetics • 2024-07-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 38750386 ↗ |
Paliperidone Palmitate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.0891/unit (~$32.67/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $128.89 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 13 Anonymous DotMD Community Micro-Logs | $52.61 / mo | View logs ↓ |
Paliperidone Palmitate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Paliperidone Palmitate RxNorm Concept ID | 858048 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.0891 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $128.89 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $52.61 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 78.00% Worth It (13 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Paliperidone Palmitate Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Paliperidone Palmitate integrating DailyMed SPL (2026-03-09), CMS NADAC ($1.0891/unit), and 13 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Paliperidone Palmitate community threads and patient logs by age, biological sex, dosage, and treatment duration.